Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

360 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-21

Study Completion Date

2023-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluation of immunogenicity and safety of inactivated COVID-19 vaccine (BBIBP-Cov) coadministered with rabies vaccine.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical Trials

NCT06548139

Rabies Virus Infection

NOT_YET_RECRUITING PHASE2

Safety, Pharmacokinetics, and Pharmacodynamic Testing of Rabies mAb CBB 1

NCT05832073

Rabies Virus Infection

UNKNOWN EARLY_PHASE1

Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4

NCT04790851

Influenza, Human Pneumonia, Pneumococcal Covid19

COMPLETED PHASE4

Safety and Immunogenicity of the Inactivated Rabies Vaccine RABIVAX-S Administered Intramuscularly and Intradermally

NCT05937113

Rabies

COMPLETED PHASE4

Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4

NCT05079152

Influenza, Human Pneumonia, Pneumococcal COVID-19 Pneumonia

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The participants aged ≥18 who had received two doses of inactivated COVID-19 vaccine were recruited and randomly assigned to one of three study groups: Co-Ad group, COVID-19 vaccine group and Rabies vaccine group.

The participants in Co-Ad group and COVID-19 vaccine group received a booster dose of inactivated COVID-19 vaccine.The participants in Co-Ad group and Rabies vaccine group received three doses of rabies vaccine for pre-exposure immunization. The participants in Co-Ad group received the first dose of rabies vaccine (Day 0) and the inactivated COVID-19 vaccine simultaneously.

Any local or systemic adverse events after vaccination will be recorded.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Rabies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Co-Ad group

A total of 120 participants received one dose of inactivated COVID-19 vaccine and three doses of rabies vaccine.

Participants received one dose of inactivated COVID-19 vaccine and rabies vaccine on Day 0, and one dose of rabies vaccine on Day 7 and Day 28.

Blood sampling was performed on Day 0, Day 28 and Day 42.

Group Type EXPERIMENTAL

coadministration

Intervention Type BIOLOGICAL

the coadministration of an inactivated COVID-19 vaccine (BBIBP-CorV) and rabies vaccine

COVID-19 vaccine group

A total of 120 participants received one dose of inactivated COVID-19 vaccine on Day 0.

Blood sampling was performed on Day 0 and Day 28.

Group Type EXPERIMENTAL

COVID-19 vaccine

Intervention Type BIOLOGICAL

received one dose of inactivated COVID-19 vaccine (BBIBP-CorV)

Rabies vaccine group

A total of 120 participants received three doses of rabies vaccine on Day 0, Day 7 and Day 28.

Blood sampling was performed on Day 0 and Day 42.

Group Type EXPERIMENTAL

rabies vaccine

Intervention Type BIOLOGICAL

received three dose of rabies vaccine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

coadministration

the coadministration of an inactivated COVID-19 vaccine (BBIBP-CorV) and rabies vaccine

Intervention Type BIOLOGICAL

COVID-19 vaccine

received one dose of inactivated COVID-19 vaccine (BBIBP-CorV)

Intervention Type BIOLOGICAL

rabies vaccine

received three dose of rabies vaccine

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants aged ≥18.
* Have the ability to understand the study procedures, voluntarily sign informed consent.
* Be able and willing to complete the entire study plan during the study follow-up period.
* Participants have not received any rabies vaccine.
* Participants have received 2 doses of inactivated COVID-19 vaccine for 6-12 months.
* The time interval between the last vaccination is ≥14 days.
* Body temperature \< 37.3 °C confirmed by clinical examination before enrollment .

Exclusion Criteria

* Participants who have received the third dose of COVID-19 vaccine.
* Participants who have previously been infected with COVID-19 or who have tested positive for SARS-CoV-2.
* Having a history or family history of convulsions, epilepsy, encephalopathy and psychosis.
* Being allergic to any component of vaccines and a history of severe allergic reactions to any vaccine.
* Participants are suffering from immunodeficiency, receiving immunosuppressant therapy (oral steroid hormones) during treatment for malignancy, or having low immunity due to HIV within 14 days before enrollment, or having congenital immune disorders in close family members.
* Injection of non-specific immunoglobulin within 1 month before enrollment.
* Participants are suffering from acute febrile diseases and infectious diseases, or have used anti-inflammatory/antiviral/antipyretic/antiallergic drugs within 3 days before enrollment.
* A history of clearly diagnosed thrombocytopenia or other clotting disorders that may contraindicate subcutaneous injection.
* Participants with severe chronic diseases or acute episodes of chronic diseases, hypertension or diabetes that cannot be controlled by drugs.
* Participants with infectious, suppurative and allergic skin diseases.
* Pregnant and lactating women.
* Other Participants whose physical conditions, as determined by the investigator, are not suitable for inclusion in clinical studies.

* Participants who had vaccine-related serious adverse reactions after vaccination.
* Systemic adverse reactions/anaphylaxis with severity ≥3 after vaccination as determined by the investigator.
* Other reasons for exclusion considered by the investigator.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes